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RESEARCH ARTICLE Open Access
Statistical methodology for age-adjustment
of the GH-2000 score detecting growth
hormone misuse
Dankmar Böhning1* , Walailuck Böhning2, Nishan Guha2,3, David A. Cowan4, Peter H. Sönksen2
and Richard I. G. Holt2
Abstract
Background: The GH-2000 score has been developed as a powerful and unique technique for the detection of growth
hormone misuse by sportsmen and women. The score depends upon the measurement of two growth hormone (GH)
sensitive markers, insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP). With
the collection and establishment of an increasingly large database it has become apparent that the score shows a
positive age effect in the male athlete population, which could potentially place older male athletes at a disadvantage.
Methods: We have used results from residual analysis of the general linear model to show that the residual of the GH-
2000 score when regressed on the mean-age centred age is an appropriate way to proceed to correct this bias. As six
GH-2000 scores are possible depending on the assays used for determining IGF-I and P-III-NP, methodology had to be
explored for including six different age effects into a unique residual. Meta-analytic techniques have been utilized to find
a summary age effect.
Results: The age-adjusted GH-2000 score, a form of residual, has similar mean and variance as the original GH-2000 score
and, hence, the developed decision limits show negligible change when compared to the decision limits based on the
original score. We also show that any further scale-transformation will not change the adjusted score. Hence the
suggested adjustment is optimal for the given data. The summary age effect is homogeneous across the six scores, and
so the generic adjustment of the GH-2000 score formula is justified.
Conclusions: A final revised GH-2000 score formula is provided which is independent of the age of the athlete under
consideration.
Keywords: GH-2000 score, Adjusting for age effects, Meta-analysis of scores, Centring and norming of scores
Background
Growth hormone is a powerful anabolic agent of consider-
able therapeutic value but also misused in sport for its ana-
bolic and lipolytic properties [1]. In order to preserve the
fairness of competition, its use is prohibited by the World
Anti-Doping Agency [2] and there is a need for methods to
detect its misuse. Two methods are presently available and
approved by the World Anti-Doping Agency (WADA); the
isoform test developed by Bidlingmaier et al. [3]) (see also
[4]) and the GH-2000 biomarker test developed by the GH-
2000 and GH-2004 projects [5]. The latter method depends
upon the measurement of two growth hormone (GH) sensi-
tive markers, insulin-like growth factor-I (IGF-I) and the
amino-terminal pro-peptide of type III collagen (P-III-NP),
both of which rise in response to exogenous GH administra-
tion [6, 7]. The measured concentrations of the biomarkers
are combined in sex-specific and age-adjusted discriminant
functions, which allow for the calculation of a score (the
GH-2000 score) on which basis the compliance of the sam-
ple’s analytical result is determined. The age correction is re-
quired because GH secretion and markers of its action rise
during childhood and reach a peak in early adulthood
before declining at a rate of ~14 % per decade [8]. Without
an adjustment for age, younger athletes are placed at a dis-
advantage. For IGF-I and P-III-NP, a model in which the log
of the marker level decreased linearly with the reciprocal of
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age fitted the data from 693 elite athlete marker levels well,
over the range of ages studied [9] and a term with the recip-
rocal for age was included in the GH-2000 score [10]. The
inverse term for age is designed to adjust for age so that the
score becomes independent of age. This is important in
order to make the test applicable to athletes of all ages.
The initial development of the GH-2000 score was based
on immunoassays that are no longer commercially avail-
able. Although the original discriminant function has
remained unchanged, the decision limits have been updated
as further experience was accumulated and new assays be-
came available [5, 11]. Currently, there are three IGF-I as-
says and two P-III-NP assays approved by WADA.
The IGF-I assays used in this study were:
 Liquid chromatography-tandem mass spectrometry
(LC-MS/MS)
 Immunotech A15729 IGF-I IRMA (Immunotech
SAS, Marseille, France)
 and Immunodiagnostic Systems iSYS IGF-I
(Immunodiagnostics Systems Limited, Boldon, UK)
The P-III-NP assays used in this analysis were:
 UniQ™ P-III-NP RIA (Orion Diagnostica, Espoo, Finland)
 Siemens ADVIA Centaur P-III-NP (Siemens Health-
care Laboratory Diagnostics, Camberley, UK).
For more details and background on these assays see
Holt et al. [5].
As these assays do not give identical results, different
GH-2000 scores are obtained with each of the combina-
tions and this means that the decision limits are differ-
ent, depending on the assay pair used.
Recent analysis of a combined database of 998 male and
931 female elite athletes [5] provides evidence that the
score is independent of age for the female population
whereas it shows a linear dependence for male athletes.
This indicates that the original inverse term for age over-
corrects for the natural decline in GH markers thereby
potentially placing older athletes at a disadvantage.
The combined database contains blood samples of ath-
letes collected at various sporting events including the
2011 International Association of Athletics Federations
(IAAF) World Athletics Championships in Daegu, South
Korea, in the following abbreviated as the Daegu sample.
Figure 1 shows the scores and their relationship to age in
597 male athletes competing in Daegu. There are 6 scores
as there are 3 assays for IGF-I (LC-MS/MS, Immunotech,
IDS) and 2 for P-IIIN-P (Siemens-Centaur, Orion). It is clear
Fig. 1 Scatterplots with regression lines for the six GH-2000 scores (GHS) available of all male athletes in the Daegu sample: Siemens-LC-MS/MS (top-left),
Siemens-Immunotech (top-middle), Siemens-IDS (top-right), Orion-LC-MS/MS (bottom-left), Orion-Immunotech (bottom-middle), Orion-IDS (bottom-right)
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from Fig. 1 that in all GH-2000 scores there is a positive age
dependency as all linear regression lines show a significant
age-effect. This positive age dependency is also seen in non-
parametric regression of the GH-2000 score on age and,
hence, is of structural nature and not caused by artefacts
such as outlying observations. There is no age effect on the
GH-2000 scores for the female population of the Daegu
sample indicating that the original age correction term per-
forms well in a new independent database (data not shown).
The purpose of this paper is to suggest and discuss
statistical methodology for adjusting the existing male
GH-2000 score for the undesirable age-effect.
Methods
The GH-2000 score
The GH-2000 score has been developed in Powrie et al.
[10], Erotokritou-Mulligan et al. [11] and Holt et al. [5].
It has the theoretical or model form
GH2000 score ¼ β0 þ β1 log IGF‐Ið Þ
þ β2 log P‐III‐NPð Þ þ β3=age ð1Þ
where the coefficients β0, β1, β2, β3 have different values
for male and female athletes. When coefficients are re-
placed by estimates the GH-2000 score for male athletes is
GH2000 score ¼ −6:586þ 2:100 log IGF‐Ið Þ
þ 2:905 log P‐III‐NPð Þ101:737=age
ð2Þ
and for female athletes
GH2000 score ¼ −8:459þ 2:195 log IGF‐Ið Þ
þ 2:454 log P‐III‐NPð Þ
 73:666=age ð3Þ
As we have seen in the previous section, the GH-2000
score shows positive age-dependency for the male popu-
lation. Adjusting for the age-effect will be considered in
the next section.
The basics of adjustment
Consider a response Y (in our case the GH-2000 score)
and an effect x (in our case the age of an athlete).
Suppose that the response Y is related to x by a linear
regression model
E Yð Þ ¼ αþ βx ð4Þ
Then, the least-squares estimate of β in (4) is given by
β^ ¼
Xn
i¼1
Y i−Y
 
xi−xð Þ
Xn
i¼1
xi−xð Þ2
ð5Þ
where the pairs (Yi, xi) represent the n sample values of
Y and x. On this basis we are able to construct a re-
sponse Y  ¼ Y −β^x adjusting for x.
The adjusted response Y *is independent of x as the
following analysis shows. This can be found in most
books on regression but it is mentioned here for com-
pleteness. Consider the least-squares-estimate of β* in
(6)
E Y ð Þ ¼ α þ βx: ð6Þ
This least-squares estimate of β* is provided as zero as
equation (7) shows:
β^
 ¼
Xn
i¼1
Y i −Y
 
xi−xð Þ
Xn
i¼1
xi−xð Þ2
¼
Xn
i¼1
Y i−β^xi− Y −β^
  
xi−xð Þ
Xn
i¼1
xi−xð Þ2
¼
Xn
i¼1
Y i−Y
 
xi−xð Þ−β^
Xn
i¼1
xi−xð Þ2
Xn
i¼1
xi−xð Þ2
¼
Xn
i¼1
Y i−Y
 
xi−xð Þ
Xn
i¼1
xi−xð Þ2
−β^
Xn
i¼1
xi−xð Þ2
Xn
i¼1
xi−xð Þ2
¼ 0:
ð7Þ
Hence Y * is independent of x. A more general result is
provided in Appendix 1.
Next, we suggest considering an adjustment of the form
Y  ¼ Y −β^ x−xð Þ: ð8Þ
The benefit of this adjustment (8) lies in the fact that
the adjusted score Y* remains on the same level as the
original score Y as
Y
 ¼ Y −β^ x−xð Þ ¼ Y : ð9Þ
The process of considering x−x is called centering. Some-
times also norming is considered in addition to centering
which is x−xð Þ=sd xð Þ where sd xð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n−1
Xn
i¼1
xi−xð Þ2
s
:
We are not considering norming here as this will not lead
to any further adjustment. To see this, we consider any
scale transformation ax of x. The original model E (Y) = α
+ βx becomes now E (Y) = α* + β* x*, where x* = ax. Then,
least squares estimates can be found as
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β^
 ¼
Xn
i¼1
Y i−Y
 
xi −x
 
Xn
i¼1
x
i
−x
 2 ¼
Xn
i¼1
Y i−Y
 
xi−xð Þa
Xn
i¼1
xi−xð Þ2a2
¼ 1
a
Xn
i¼1
Y i−Y
 
xi−xð Þ
Xn
i¼1
xi−xð Þ2
¼ 1
a
β^
ð10Þ
Hence the adjusted response (11)
Y  ¼ Y −β^x ¼ Y − 1
a
β^
 
ax ¼ Y −β^x ð11Þ
is indeed identical to the original adjustment Y −β^x and
does not lead to anything new. A more general result is
provided in Appendix 2. Hence we stay with the adjust-
ment Y  ¼ Y −β^ x−xð Þ’, provided in (8), as the final form
of adjustment.
Adjusting the GH-2000 score
To adjust the GH-2000 score, we consider the regres-
sion of the GH-2000 score on age. Table 1 shows 6
age-effects for the 6 GH-2000 scores (as there are 2
assays for measuring P-III-NP and 3 assays for meas-
uring IGF-I).
For simplicity and ease of use by the anti-doping
laboratories, it is important that we do not create an
age adjustment for each assay pairing. Thus we need to
include the age adjustment within the generic GH-2000
score (independent of the specific assay pairing used).
To accomplish this task we have applied ideas from
meta-analysis. We consider each GH-2000 score using
a specific assay combination as a realisation from mul-
tiple possible assay combinations.
This is similar to a meta-analysis approach in
which studies aiming to estimate a certain effect are
considered as realisation from a universe of possible
studies.
Hence we use
β ¼
Xk
i¼1
wiβ^i=
Xk
i¼1
wi ð12Þ
where k = 6 is the number of different assay combina-
tions used and β^i is the estimated age effect, and wi is
the inverse of the estimated variance (the squared values
in column 3 of Table 1). Hence β is an average of the
estimated effect.
Results
In our case, we find β = 0.032. Figure 2 shows this ana-
lysis graphically. As all assay-specific age effects are
similar in their standard error, all weights are similar.
More details on the meta-analysis approach are given in
Appendix 3.
To investigate the appropriateness of the meta-analytic
weighted average approach (are the age-effects for the
six scores similar enough to be validly combined in a
weighted average?) a heterogeneity analysis was per-
formed. The X2-test of homogeneity χ2 ¼
X6
i¼1
β^i−β
 2
var β^i
 
delivers a value of 4.37 which has a non-significant p-value
of 0.498 by 5 df. Hence the approach we have taken is
justified (details are given in the Appendix 3).
From the meta-analysis, we achieve the formula for
the male athletes:
GH‐2000 score‐adj ¼ GH‐2000 score – 0:032 age ‐ 25:09ð Þ
As the mean age for male athletes is 25.09 years and
the GH-2000 is calculated as:
GH‐2000 score ¼  6:586 þ 2:905 log P‐III‐NPð Þ
þ 2:100 log IGF‐Ið Þ – 101:737=age
the adjusted score formula becomes:
GH 2000 score‐adj ¼  5:783 þ 2:905 log P‐III‐NPð Þ
þ 2:100 log IGF‐Ið Þ – 101:737=age
– 0:032 age:
ð13Þ
Figure 3 shows a scatterplot of the six age-adjusted
GH-2000-scores. It clearly shows that the age-effect is
removed as it is expected from the above theory.
Effect on the current WADA decision limits
Although this adjustment will lead to changes in the
individual GH-2000 score of an athlete, it has negligible
effect on the decision limits. The decision limits are
most important in practice as they provide the cut-off
value above which the athlete’s GH-2000 score value is
considered to be positive. Following Holt et al. [5] these
are constructed using the 1 in 10,000 false positive rate as
Table 1 Estimated β-coefficients of the age-effects for the six
GH-2000 scores and their associated standard errors
GH-2000 score β^ age S.E.
P-III-NP assay IGF-I assay
Siemens LC-MS/MS 0.0418 0.0082
Siemens Immunotech 0.0261 0.0086
Siemens IDS 0.0359 0.0070
Orion LC-MS/MS 0.0363 0.0077
Orion Immunotech 0.0202 0.0085
Orion IDS 0.0318 0.0077
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Fig. 2 Meta-analytic results for the six age-effects of the GH-2000 scores on age (I-V stands for overall inversely weighted and provides the
summary estimate of the age-affect); more details are given in the appendix, the arrow-to-right indicates that the right confidence limit falls
outside the plotting area
Fig. 3 Scatterplots with regression lines for the six age-adjusted GH-2000 scores (GHS) of all male athletes in the Daegu-sample in the order of
their appearance: Siemens-LC-MS/MS (top-left), Siemens-Immunotech (top-middle), Siemens-IDS (top-right), Orion-LC-MS/MS (bottom-left),
Orion-Immunotech (bottom-middle), Orion-IDS (bottom-right)
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DL ¼ y þ 3:72sþ u ð14Þ
where y and s are mean and standard deviation of the
respective GH-2000 score. u is a sample uncertainly
term defined as
u ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2
n
1þ 3:72
2
n
 s
ð15Þ
where n is the sample size. Table 2 shows the details, in
particular, a comparison between GH-2000 scores with
and without adjustment
Distribution of adjusted GH-2000 scores
The construction of the decision limits for GH-2000
biomarker methodology is dependent on a normal distri-
bution of GH-2000 scores among clean athlete. This was
assessed using probability plotting and the Anderson-
Darling test for normality which provided clear evidence
that all six scores were normally distributed (Fig. 4).
Table 2 Descriptive statistics including decision limits for the 6 unadjusted and adjusted GH-2000 scores
Assay pair n mean sa Mean + 3.72*s ub DLc
P-III-NP IGF-I
Siemens LC-MS Unadjusted Adjusted 947 947 6.5393 6.5382 1.2412 1.2424 11.1566 11.1599 0.1872 0.1874 11.34 11.35
Siemens Immunotech Unadjusted Adjusted 971 971 6.4292 6.4287 1.3189 1.3284 11.3355 11.3703 0.1965 0.1979 11.53 11.57
Siemens IDS Unadjusted Adjusted 970 970 5.9935 5.9931 1.1925 1.1954 10.4296 10.4400 0.1777 0.1782 10.61 10.62
Orion LC-MS Unadjusted Adjusted 966 966 4.7062 4.7047 1.2902 1.2976 9.5057 9.5318 0.1927 0.1938 9.70 9.73
Orion Immunotech Unadjusted Adjusted 999 999 4.5984 4.5984 1.3925 1.4077 9.7785 9.8350 0.2045 0.2068 9.98 10.04
Orion IDS Unadjusted Adjusted 992 992 4.1614 4.1611 1.2522 1.2610 8.8196 8.8520 0.1846 0.1859 9.00 9.04
as is the standard deviation, bu is the uncertainty correction (13), cDL is the decision limit (12)
Fig. 4 Probability plots for the six GH-2000 scores (GHS) adjusted for age; AD stand for Anderson-Darling test of normality and the P-value refers
to the null-hypothesis of normality so that values larger than 0.05 do not lead to rejection of normality
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Discussion
We are suggesting this adjustment for the male elite
athlete population only, as the female population does
not show age dependency. It could be demonstrated that
the proposed adjustment of the GH-2000 score removes
the positive age dependency.
Furthermore, the age-adjustment of the score is also
beneficial with respect to the normality of the scores as
the probability plot in Fig. 4 shows that all scores appear
to be normal.
The GH-2000 and GH-2004 teams have previously pub-
lished the rationale and background to the development
of decision limits for the GH-2000 biomarker detection
method [5, 10].
It was always envisaged that a dynamic approach would
be taken towards refining the decision limits as further
data became available. Our recent investigations have
shown that the age-adjustment in the male discriminant
function, which was derived the original GH-2000 cross-
sectional elite athlete study [9, 10], over-corrects for age in
male athletes in our more recent cohorts. The effect of
this over-correction is to place older male athletes at a
slight disadvantage compared with their younger peers,
for whom the sensitivity of the test is reduced. The
original age correction for women remained valid in the
later cohorts. We have used the most recent dataset, on
which the current decision limits are based, to add a
smaller further adjustment to the discriminant function to
address this issue.
When undertaking this analysis, we used several prin-
ciples to guide out work: 1) we wanted to ensure that
the updated male discriminant function was unaffected
by age in order to make the test equally fair and effect-
ive for athletes of all ages; 2) the change in age correc-
tion would have a minimal effect on the current
decision limits; and 3) a single age adjustment could be
applied for all assay pairings. In order to minimise the
effect on the current decision limits, we used a method
that centred the data. By doing so the mean GH-2000
scores were virtually unaffected. There was a trivial
change to the SDs and consequently the decision limits,
which are based on the mean and SD, were unchanged.
The age adjustment varies slightly by assay pairing and
in order to overcome this, we adapted meta-analytical
methodology to derive a common age adjustment for
all the combinations. There was no evidence of hetero-
geneity between the assay pairings and each contrib-
uted to the final adjustment equally, providing support
for this approach.
Conclusion
In conclusion, we have created a small further age
adjustment for male athletes to correct the age bias in-
troduced with the original discriminant formula. This
has no effect on the decision limits and should be easily
introduced into anti-doping testing.
Appendix 1
Independence of residuals from model covariates
Consider a general linear model Y = X β + ε where Y is a
n-vector of responses, X is the design matrix containing
the n-values of p covariates, ε is a n-vector of errors, and
β is a p-vector of unknown parameters. Then, the least-
squares estimate for β is given as
β^ ¼ XTX −1XTY ðA1Þ
and the vector of residuals Y  ¼ Y−Xβ^ . Regressing Y*
on X leads to the general linear model
Y  ¼ Xβ þ ε ðA2Þ
and the least-squares estimate of β* is given as
β^
 ¼ XTX −1 XTY  ¼ XTX −1XT Y−Xβ^
 
¼ XTX −1XT Y−X XTX −1XTYh i
¼ XTX −1XTY− XTX −1XTX XTX −1XTY
¼ XTX −1XTY− XTX −1XTY ¼ 0;
ðA3Þ
showing that the residuals are independent from all
covariates included in the model. See also Sen and
Srivastava [12].
Appendix 2
Invariance of the effect estimates with respect to scale
transformations
Consider a general linear model Y = X β + ε where Y is
a n-vector of responses, X is the design matrix contain-
ing the n-values of p covariates, ε is a n-vector of
errors, and β is a p-vector of unknown parameters.
Now let A be an invertible p × p matrix and XA the
associated scale-transformation of the design matrix.
Then, the least-squares estimate of the transformed
model Y = XAβ* + ε* is given as
β^
 ¼ ATXTXA −1 ATXTY ¼ XTXA −1 AT −1ATXTY
¼ XTXA −1XTY ¼ A−1 XTX −1XTY :
ðB1Þ
It follows that the residual with respect to the scale-
transformed design matrix
Y−XAβ^
 ¼ Y−XAA−1 XTX
 −1
XTY
¼ Y−X XTX −1XTY ¼ Y−Xβ^
ðB2Þ
is identical to the residual of the untransformed design
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matrix. See also [12]. As a consequence norming (for
example by standard deviations of covariates) of the
covariates will not change the residuals.
Appendix 3
Heterogeneity analysis
Here we give more details on the meta-analytic approach
we have taken. Figure 5 shows the various elements
involved in the meta-analysis.
The basic elements are the six GH2000 scores with
their age-effects and weights according to the inverse
variance (similar variance). The two bottom rows
show the summary effect with and without heterogen-
eity. Both are virtually identical, as there is no hetero-
geneity (I2 = 0, no variation due to heterogeneity). In
case there is heterogeneity we would consider the
DerSimonian-Laird approach which incorporates het-
erogeneity into the weighting scheme. In our case,
both analyses lead to the same result. All analysis is
based on the add-on package METAN of the statis-
tical software STATA14 [13].
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